Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff yesterday was unsurprising in light of the stock strength over the past year and “muted” 2025 EBITDA guidance, the analyst tells investors in a research note. The firm says limited near-term catalysts acted as a pivot to reverse Teva’s stock momentum. However, it stays confident in the company’s ability to sustain growth across all its segments.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.